Retrophin proposes acquisition of Clinuvel Pharma for $95 million

28 July 2014
mergers-acquisitions-big

The USA’s Retrophin (Nasdaq: RTRX) has submitted an unsolicited $95 million takeover proposal to the board of directors of Australian biotech firm Clinuvel Pharmaceuticals, the shares of which rocketed 28% to A$2.15 in mid-morning trading today.

Retrophin has proposed a “scheme of arrangement” for all of the shares of Clinuvel stock that Retrophin does not own for (1) 0.175 Retrophin shares per Clinuvel share, or (2) A$2.17 per share in cash. Retrophin currently owns around 4.88% of Clinuvel, which is developing therapies for rare skin diseases

Retrophin aims to unlock value of skin drug candidate Scenesse

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical